These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 17339744)

  • 21. The role of magnesium binders in chronic kidney disease.
    Spiegel DM
    Semin Dial; 2007; 20(4):333-6. PubMed ID: 17635824
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Different routes bridging calcium in Japanese hemodialysis patients.
    Hamano T; Fujii N; Ito T; Imai E
    Ther Apher Dial; 2005 Feb; 9(1):32-8. PubMed ID: 15828903
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adherence to K/DOQI guidelines for calcium-based phosphate binders in clinical practice.
    Shastri J; Tran A; Covit A; Pepe J; Sherman RA
    J Ren Nutr; 2008 Jul; 18(4):370-4. PubMed ID: 18558302
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Effect of non-calcium-based phosphate binders on vascular calcifications in patients on hemodialysis: clinical experience and hypotheses].
    Bolasco P
    G Ital Nefrol; 2011; 28(4):357. PubMed ID: 21809303
    [No Abstract]   [Full Text] [Related]  

  • 25. Impact of the Kidney Disease Outcomes Quality Initiative (KDOQI) Clinical Practice Guidelines for Bone Metabolism and Disease in a large dialysis network.
    Wald R; Tentori F; Tighiouart H; Zager PG; Miskulin DC
    Am J Kidney Dis; 2007 Feb; 49(2):257-66. PubMed ID: 17261428
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Mechanism and therapy of vascular calcification].
    Hara S; Yokoyama K
    Clin Calcium; 2004 May; 14(5):752-5. PubMed ID: 15577037
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Vascular calcification in patients with end-stage renal disease.
    Floege J; Ketteler M
    Nephrol Dial Transplant; 2004 Aug; 19 Suppl 5():V59-66. PubMed ID: 15284362
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mineral metabolism disturbances in patients with chronic kidney disease.
    Kestenbaum B; Belozeroff V
    Eur J Clin Invest; 2007 Aug; 37(8):607-22. PubMed ID: 17635571
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Clinical evidence and treatment for optimum concentration of parathyroid hormone, calcium and phosphate in chronic renal failure].
    Hoshino J; Ubara Y; Takaichi K
    Clin Calcium; 2004 May; 14(5):731-7. PubMed ID: 15577034
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Are CSN and NKF-K/DOQI mineral metabolism guidelines for hemodialysis patients achievable? Results from a provincial renal program.
    Wazny LD; Raymond CB; Lesperance EM; Bernstein KN
    CANNT J; 2008; 18(2):36-41, 44-50; quiz 42-3, 51-2. PubMed ID: 18669010
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Sevelamer hydrochloride prevents ectopic calcification of blood vessels].
    Fukushima N; Nagano N
    Clin Calcium; 2004 Jun; 14(6):116-22. PubMed ID: 15577065
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Vitamin D deficiency and associated factors in hemodialysis patients.
    Jean G; Charra B; Chazot C
    J Ren Nutr; 2008 Sep; 18(5):395-9. PubMed ID: 18721733
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Managing bone parameters in dialysis patients: international guideline conflicts.
    Faull RJ
    Semin Dial; 2007; 20(3):191-4. PubMed ID: 17555479
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cardiovascular calcification in patients with end-stage renal disease.
    Pecovnik-Balon B
    Ther Apher Dial; 2005 Jun; 9(3):208-10. PubMed ID: 15966990
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Evaluation of coronary artery calcification in ESRD patients].
    Yokoyama K
    Clin Calcium; 2004 Jun; 14(6):109-15. PubMed ID: 15577064
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Treatment with phosphate binder (sevelamer hydrochloride, calcium carbonate) based on PTH].
    Sato M; Fukazawa S; Yasuda T; Akatsuka T; Tozawa S; Niida Y; Hashimoto N; Mochizuki T; Koike T
    Clin Calcium; 2005 Sep; 15 Suppl 1():23-8; discussion 28-9. PubMed ID: 16272625
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sevelamer treatment strategy in peritoneal dialysis patients: conventional dose does not make best use of resources.
    Chow KM; Szeto CC; Kwan BC; Leung CB; Li PK
    J Nephrol; 2007; 20(6):674-82. PubMed ID: 18046669
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [CKD-MBD (Chronic Kidney Disease-Mineral and Bone Disorder). Atheroma and vascular calcification in hemodialysis patients].
    Joki N; Tanaka Y
    Clin Calcium; 2010 Jul; 20(7):1061-6. PubMed ID: 20585185
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Chronic kidney disease (CKD) and bone. Targets of serum calcium, phosphate, and parathyroid hormone levels and their controls in maintenance dialysis patients].
    Akiba T
    Clin Calcium; 2009 Apr; 19(4):537-44. PubMed ID: 19329833
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sevelamer hydrochloride prevents ectopic calcification and renal osteodystrophy in chronic renal failure rats.
    Katsumata K; Kusano K; Hirata M; Tsunemi K; Nagano N; Burke SK; Fukushima N
    Kidney Int; 2003 Aug; 64(2):441-50. PubMed ID: 12846739
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.